Ronnie Aronson1, Gagik Galstyan2, Margalit Goldfracht3, Saud Al Sifri4, Lisa Elliott5, Kamlesh Khunti6. 1. LMC Diabetes and Endocrinology, Toronto, Canada. Electronic address: ronnie.aronson@lmc.ca. 2. Endocrinology Research Center, Moscow, Russian Federation. 3. Clalit Health Services, The Technion, Haifa, Israel. 4. Al Hada Military Hospital, Taif, Saudi Arabia. 5. Novo Nordisk A/S, Søborg, Denmark. 6. Diabetes Research Centre, University of Leicester, Leicester, UK.
Abstract
AIMS: The Hypoglycaemia Assessment Tool (HAT) study investigated the health economic impact of hypoglycaemic events in 24 countries, including countries without previously published data on hypoglycaemia. METHODS: Self-assessment questionnaires and patient diaries (4-week prospective period) were completed by adults with type 1 (T1D) or type 2 diabetes (T2D) treated with insulin for more than 12 months (N = 27,585). RESULTS: Direct economic impacts of hypoglycaemia during the 4-week prospective period, included increased blood glucose monitoring (reported by 69.7% [T1D] and 60.9% [T2D] of patients), hospitalisation (T1D 2.1%; T2D 3.4% of patients) and medical contact (clinic or telephone; T1D 3.8%; T2D 6.8% of patients). Regional variation in medical contact and hospitalisation was found, with the highest usage in Russia (T1D 17.1%; T2D 17.3%), and Latin America (T1D 5.2%; T2D 6.8%) respectively. Indirect economic impacts following hypoglycaemia included loss of productivity due to absence from work or study; 3.9% (T1D) and 6.2% (T2D) of patients. Regional differences in work productivity were noted among patients with T2D, with a low prevalence in Northern Europe and Canada (0.9%) and high in Southeast Asia (14.6%). CONCLUSIONS: This study shows that hypoglycaemia has a significant but variable impact on the economics of diabetes healthcare globally.
AIMS: The Hypoglycaemia Assessment Tool (HAT) study investigated the health economic impact of hypoglycaemic events in 24 countries, including countries without previously published data on hypoglycaemia. METHODS: Self-assessment questionnaires and patient diaries (4-week prospective period) were completed by adults with type 1 (T1D) or type 2 diabetes (T2D) treated with insulin for more than 12 months (N = 27,585). RESULTS: Direct economic impacts of hypoglycaemia during the 4-week prospective period, included increased blood glucose monitoring (reported by 69.7% [T1D] and 60.9% [T2D] of patients), hospitalisation (T1D 2.1%; T2D 3.4% of patients) and medical contact (clinic or telephone; T1D 3.8%; T2D 6.8% of patients). Regional variation in medical contact and hospitalisation was found, with the highest usage in Russia (T1D 17.1%; T2D 17.3%), and Latin America (T1D 5.2%; T2D 6.8%) respectively. Indirect economic impacts following hypoglycaemia included loss of productivity due to absence from work or study; 3.9% (T1D) and 6.2% (T2D) of patients. Regional differences in work productivity were noted among patients with T2D, with a low prevalence in Northern Europe and Canada (0.9%) and high in Southeast Asia (14.6%). CONCLUSIONS: This study shows that hypoglycaemia has a significant but variable impact on the economics of diabetes healthcare globally.
Authors: Thomas Danne; Jeremy Pettus; Andrea Giaccari; Bertrand Cariou; Helena Rodbard; Stuart A Weinzimer; Mireille Bonnemaire; Sangeeta Sawhney; John Stewart; Stella Wang; Rita de Cassia Castro; Satish K Garg Journal: Diabetes Technol Ther Date: 2019-09 Impact factor: 6.118
Authors: Edward B Jude; Maciej T Malecki; Ricardo Gomez Huelgas; Martin Prazny; Frank Snoek; Tsvetalina Tankova; Dario Giugliano; Kamlesh Khunti Journal: Diabetes Ther Date: 2022-03-11 Impact factor: 2.945
Authors: Eric Renard; Hiroshi Ikegami; André Gustavo Daher Vianna; Paolo Pozzilli; Sandrine Brette; Zsolt Bosnyak; Felipe Lauand; Anne Peters; Valerie Pilorget; Dubravka Jurišić-Eržen; Jothydev Kesavadev; Jochen Seufert; Emma G Wilmot Journal: Diabetes Metab Res Rev Date: 2021-03-02 Impact factor: 4.876